Rathbones Group PLC Lineage Cell Therapeutics, Inc. Transaction History
Rathbones Group PLC
- $22 Billion
- Q2 2025
A detailed history of Rathbones Group PLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Rathbones Group PLC holds 35,000 shares of LCTX stock, worth $62,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,000
Previous 35,000
-0.0%
Holding current value
$62,300
Previous $15,000
106.67%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
141Shares Held
106MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$88.2 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$17 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$15.1 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$12.1 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$9.6 Million6.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $302M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...